Oncopeptides starts European commercialization of myeloma drug in Germany
Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in…
October 3, 2022 - 2 minutes
Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in…
A Swedish biotech company says it believes its treatment could be the ‘canary in the…